Results 71 to 80 of about 31,381 (233)

The Role of microRNAs in Regulating Cancer Cell Response to Oxaliplatin-Containing Regimens

Technology in Cancer Research & Treatment, 2023
Oxaliplatin (cyclohexane-1,2-diamine; oxalate; platinum [2+]) is a third-generation chemotherapeutic drug with anticancer effects. Oxaliplatin has a role in the treatment of several cancers.
Ali Tavakoli Pirzaman MD, Manijeh Ebrahimzadeh Pirshahid MD, Bahareh Babajani MS, Amirhossein Rahmati MS, Shokat Niknezhad MS, Rezvan Hosseinzadeh MD, Mehdi Taheri MS, Faezeh Ebrahimi-Zadeh MD, Shahrbanoo Doostmohamadian MS, Sohrab Kazemi PhD   +9 more
doaj   +1 more source

Targeting Tex10 Overcomes Oxaliplatin Resistance by Competitively Disrupting the Non‐Canonical BAF Complex in Colorectal Cancer

Advanced Science, EarlyView.
This study reveals that Tex10 drives oxaliplatin resistance in colorectal cancer by competitively binding BRD9 to disrupt the ncBAF complex, thereby suppressing AMBRA1 transcription and ULK1‐mediated autophagy. Gemcitabine is identified as a direct Tex10 inhibitor that restores autophagy and overcomes resistance.
Ping Xu, Jie Huang, Xiaojin Gao, Lin Deng, Yanheng Deng, Denglu Wang, Chunlei Yu, Yunxiang Zhang, Jingdong Li, Xiaocong Xiang   +9 more
wiley   +1 more source

Lnc-RP11-536 K7.3/SOX2/HIF-1α signaling axis regulates oxaliplatin resistance in patient-derived colorectal cancer organoids

Journal of Experimental & Clinical Cancer Research, 2021
Background Resistance to oxaliplatin is a major obstacle for the management of locally advanced and metastatic colon cancer (CC). Although long noncoding RNAs (lncRNAs) play key roles in CC, the relationships between lncRNAs and resistance to oxaliplatin
Qingguo Li, Huizhen Sun, Dakui Luo, Lu Gan, Shaobo Mo, Weixing Dai, Lei Liang, Yufei Yang, Midie Xu, Jing Li, Peiyong Zheng, Xinxiang Li, Yan Li, Ziliang Wang   +13 more
doaj   +1 more source

METTL7A Downregulation Drives SLC1A5‐Mediated Glutamine Competition to Promote Tumor Proliferation and Suppress CD8+ T Cell Immunity in Gastric Cancer

Advanced Science, EarlyView.
GC cells enhance glutamine accumulation by upregulating SLC1A5 expression. This upregulation not only boosts GC cell proliferation, but also outcompetes CD8+ T cells for glutamine and suppresses their antitumor immunity. Mechanistically, METTL7A deficiency in GC induces SLC1A5 overexpression via an m6A‐dependent pathway and N‐glycosylation ...
Mingjun Sun, Shuwei Dang, Dazhi Zhou, Lixian Ding, Xun Sun, Wei Suo, Jirui Niu, Qingzhu Yang, Zhicheng Zhang, Yanyan Sun, Jinxing Li, Zhongsheng Chen, Tao Ban, Yingji Wang, Tianzhu Li, Ming Liu, Guodong Li   +16 more
wiley   +1 more source

Epigenetic Inactivation of the BRCA1 Interactor SRBC and Resistance to Oxaliplatin in Colorectal Cancer [PDF]

JNCI: Journal of the National Cancer Institute, 2013
A major problem in cancer chemotherapy is the existence of primary resistance and/or the acquisition of secondary resistance. Many cellular defects contribute to chemoresistance, but epigenetic changes can also be a cause.A DNA methylation microarray was used to identify epigenetic differences in oxaliplatin-sensitive and -resistant colorectal cancer ...
C. Moutinho, A. Martinez Cardús, C. Santos, V. Navarro Pérez, E. Martínez Balibrea, E. Musulen, F. . J. Carmona, A. Sartore Bianchi, A. Cassingena, S. Siena, E. Elez, J. Tabernero, R. Salazar, A. Abad, M. Esteller   +14 more
openaire   +4 more sources

miR-122 Targets X-Linked Inhibitor of Apoptosis Protein to Sensitize Oxaliplatin-Resistant Colorectal Cancer Cells to Oxaliplatin-Mediated Cytotoxicity

Cellular Physiology and Biochemistry, 2018
Background/Aims: Although oxaliplatin is one of the most effective chemotherapeutic drugs used to treat colorectal cancer (CRC), long-term administration usually induces acquired drug resistance during the course of treatment.
Yongqiang Hua, Yaodong Zhu, Jijie Zhang, Zhenfeng Zhu, Zhouyu Ning, Hao Chen, Luming Liu, Zhen Chen, Zhiqiang  Meng   +8 more
doaj   +1 more source

Overcoming Drug Resistance by Paclitaxel Resistance in Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
In the murine triple‐negative breast cancer (TNBC) model, chemotherapy effectively increases tumor neoantigen burden (TNB). Here, the study constructs a liposomal nanovaccine using antigens derived from in vitro chemotherapy‐treated paclitaxel‐resistant TNBC 4T1 cells.
Bo Chen, Yangyi Wang, Tingting Li, Changqing Guo, Zhe Xie, Zhixian Zhang, Xinghua Han, Wei Wang, Jian Wang, Xiaopeng Ma, Yuanzeng Min   +10 more
wiley   +1 more source

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, EarlyView.
Abstract Irinotecan, a topoisomerase I inhibitor, is available as both non‐pegylated and pegylated formulations. The non‐pegylated formulation is licensed for use in advanced colorectal cancer either in combination with other agents or as monotherapy.
Dharmisha Chauhan, Cinzia Dello Russo, Jack Thompson, Dyfrig A. Hughes, Katherine Payne, Maria Tsakiroglou, Paul Ross, Rena Chauhan, Simon Jenkinson, Jessica Keen, Sophie Harding, Eleanor Lau, Michael Braun, Roshan Agarwal, Richard Adams, Elisabeth Rolf, Farah Al‐Sheikhli, Sarah Mitchell, Ruth Hammond, Rosie Roberts, Lorna Cairns, Shirley Heggarty, Janet Graham, Justin Mencel, Munir Pirmohamed   +24 more
wiley   +1 more source

Development of a prognostic model for chemotherapy response and identification of TNFAIP2 as a target in colorectal cancer

Scientific Reports
Oxaliplatin, a key chemotherapeutic agent, often induces resistance in colorectal cancer (CRC) treatment, highlighting the urgent need for reliable biomarkers to predict treatment efficacy.
Cheng Zhou, Chuan-Hai Xu, Min Xu, Xin-Kun Huang, Bin Zhu   +4 more
doaj   +1 more source

Exosomal transfer of macrophage-derived miR-223 confers oxaliplatin resistance in gastric cancer

Zhongguo aizheng zazhi, 2021
Background and purpose: Chemotherapy resistance is an important factor resulting in poor prognosis of gastric cancer patients. The elucidation of molecular mechanisms underlying chemoresistance is helpful to provide new therapeutic strategy, which has ...
郑培明, 李俊蒙, 张　鹏, 高　岚   +3 more
doaj